- Addiction Medicine
- Allergy/ Immunology
- Cardiovascular Disease
- Emergency Medicine
- Family Medicine
- Infectious Disease
- Internal Medicine
- Medical Oncology
- Obstetrics and Gynaecology
- Otorhinolaryngology or ENT (ear, nose and throat)
- Palliative Care
- Physical Therapy
- Sport Medicine
- Travel Medicine
By Dr. Rosemary Basson on May 21, 2014
Aside from testosterone replacement to younger men with proven testosterone deficiency, evidence of benefit from hormonal or pharmacological therapy to increase sexual desire is minimal.
When vulvovaginal atrophy involves loss of genital sexual sensitivity: local (vaginal) dehydroepiandrosterone (DHEA) shows promise
By Dr. Rosemary Basson on December 3, 2013
Recent studies have shown that the local delivery of the main precursor hormone of testosterone and estrogen, dehydroepiandrosterone (DHEA) effectively treats dyspareunia and dryness from VVA and does not increase serum levels of estrogen and testosterone.
By Dr. Rosemary Basson on June 10, 2013
How to manage PVD is an extremely common question. PVD affects 12 -15 % women most of whom are relatively young. The common co-morbidity of PVD strongly supports a chronic pain approach.
By Dr. Rosemary Basson on August 15, 2011
Although men with repeatedly low serum testosterone levels typically have low sexual desire, no such link has been identified in women.